Epoetin alfa-epbx: a new entrant into a crowded market. a historical review of the role of erythropoietin stimulating agents and the development of the first epoetin biosimilar in the United States

Anand, Sid; Al-Mondhiry, Jafar; Fischer, Katrina; Glaspy, John A.

doi:10.1080/17512433.2021.1863786

Cited by 3 publications

(1 citation statement)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Epoetin alfa-epbx (RetacritTM) shares the same amino acid sequence and similar carbohydrate composition as epoetin alfa (EpogenTM). In 2018, the protein was approved by the FDA, making it the first biosimilar EPO molecules approved in the USA [97]. Darbepoetin alfa (DA, Aranesp), an alternative agent of Epoetin alfa and a hyperglycosylated EPO analog, is a novel ESA with two additional N-glycosylation sites accompanied by 22 sialic acid moieties.…”

Section: Advances In Epo Derivativesmentioning

confidence: 99%

Erythropoietin in Optic Neuropathies: Current Future Strategies for Optic Nerve Protection and Repair

Lai

Lin

et al. 2022

IJMS

View full text Add to dashboard Cite

Erythropoietin (EPO) is known as a hormone for erythropoiesis in response to anemia and hypoxia. However, the effect of EPO is not only limited to hematopoietic tissue. Several studies have highlighted the neuroprotective function of EPO in extra-hematopoietic tissues, especially the retina. EPO could interact with its heterodimer receptor (EPOR/βcR) to exert its anti-apoptosis, anti-inflammation and anti-oxidation effects in preventing retinal ganglion cells death through different intracellular signaling pathways. In this review, we summarized the available pre-clinical studies of EPO in treating glaucomatous optic neuropathy, optic neuritis, non-arteritic anterior ischemic optic neuropathy and traumatic optic neuropathy. In addition, we explore the future strategies of EPO for optic nerve protection and repair, including advances in EPO derivates, and EPO deliveries. These strategies will lead to a new chapter in the treatment of optic neuropathy.

show abstract

Section: Advances In Epo Derivativesmentioning

confidence: 99%

Erythropoietin in Optic Neuropathies: Current Future Strategies for Optic Nerve Protection and Repair

Lai

Lin

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

The effect of medical cannabis in inflammatory bowel disease: analysis from the UK Medical Cannabis Registry

Dalavaye

Erridge

Nicholas

et al. 2022

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Patient blood management in the ICU

Neef¹,

Blum²,

Hof³

et al. 2022

European Journal of Anaesthesiology Intensive Care

View full text Add to dashboard Cite

The majority of ICU patients are anaemic. Anaemia is associated with worse outcomes and a necessity for red blood cell transfusions. ICU patients are a heterogeneous patient group with a broad spectrum of main diagnoses and comorbidities. Evidence-based transfusion trigger guidelines have been established that are dependent on comorbidities. Special attention has been given to blood saving measures and point-of-care diagnosis of coagulation disorders in ICU patients. The administration of intravenous iron and erythropoiesis-stimulating agents can provide useful and individualised alternatives to the administration of red blood cell concentrates in treatment of iron deficiency anaemia. In presence of inflammation and infection, it is challenging to identify the cause of anaemia. The hepcidin-ferroportin pathway may facilitate the diagnosis of anaemia in ICU patients and indicate novel targets in anaemia treatment. This review article presents patient blood management measures and summarises the current literature on transfusion thresholds and alternative therapeutic options using intravenous iron and erythropoiesis-stimulating agents with a key focus on the ICU.

show abstract

Epoetin alfa-epbx: a new entrant into a crowded market. a historical review of the role of erythropoietin stimulating agents and the development of the first epoetin biosimilar in the United States

Cited by 3 publications

References 39 publications

Erythropoietin in Optic Neuropathies: Current Future Strategies for Optic Nerve Protection and Repair

Erythropoietin in Optic Neuropathies: Current Future Strategies for Optic Nerve Protection and Repair

The effect of medical cannabis in inflammatory bowel disease: analysis from the UK Medical Cannabis Registry

Patient blood management in the ICU

Contact Info

Product

Resources

About